Celgene stock: buy or sell?
August 22nd, 2019
Celgene Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapies for the treatment of cancer and inflammatory diseases worldwide.
Should I buy Celgene stock?Even if you are a experienced or a novel trader, best trading results come from using an investing strategy that never leaves to random or subjective opinions when is the best moment to buy or sell stocks. Trading strategies are meant for helping you in the decision process of what stocks to choose and when is the best moment to buy them. At Stocks2.com, we use very simple but trusted and powerful trend following trading strategies. Simple things usually work the best.
None of our preferred buy setups matches with Celgene stock situation right now, hence this is not a suitable entry point.
|New all-time high||No|
|New 52 week high||No|
|Price crossing up 200d MA||No|
|100d MA crossing up 200d MA||No|
Is Celgene stock a buy?
Financial institutions and banks post stock ratings everyday.At Stocks2.com, we collected 15 ratings published for CELG stock in the last month.
|Date||Analyst / Broker||Previous rating||Current rating|
|2019-4-1||William Blair||Outperform||Market Perform|
|2019-4-1||Sanford C. Bernstein||Outperform||Market Perform|
|2019-2-1||Jefferies Financial Group||Buy||Hold|
|2019-1-4||Robert W. Baird||Neutral||Outperform|
|2019-1-3||Wells Fargo & Co||n/a||Hold|
Celgene stock analysis
Celgene shares remained stable 0.03% to $95.71 today.
Shares of Celgene closed today at $95.71 and remained stable a neutral 0.03%. CELG shows a strong short term uptrend with several rising tops and rising bottoms. Since its last bottom on August 15th, CELG climbed unceasignly breaking out above its last top at 95.59. Since April when SMA100d and SMA200d crossed up, CELG price gained $2.04 per share (2.18%). Since Friday when CELG stock price broke up the SMA100d line, it gained $2.40 (2.57%).
Shares of Celgene closed this week at $95.71 and appreciated a slightly good 1.02%.
The downtrend marked by CELG has left consecutive falling peaks and bottoms. There is a chance to rebound and reverse this situation if price can hold above the level. Since SMA20d and SMA40w crossed up by mid April, CELG price climbed $1.57 per share (1.67%). Since late December 2018 when CELG stock price broke up the SMA40w line, it gained $33.28 (53.31%).
Celgene stock price history
Celgene stock went public on July 28th, 1987 with a price of $0.481. Since then, CELG stock grew a 19,839.60%, with an average of 620.00% per year. If you had invested right after CELG's IPO a $1,000 in Celgene stock in 1987, it would worth $198,396.00 today.
1: Adjusted price after possible price splits or reverse-splits.
Celgene stock historical price chart
CELG stock reached 52-week highs on June at $98.97, and all-time highs 2017-10-02 with a price of 147.17.
Celgene stock price target is $101.40Predicting the price evolution of a stock or any financial instrument in a reliable and repeatable way is probably impossible. However, many stock price predictions are published every day by banks, financial institutions and independent analysts. The accuracy of these stock price predictions is not very high, and you should not blindly believe and make decisions only based on what this ratings or price target predictions say. We detected 7 price forecasts for Celgene stock released in the last 30 days:
|Date||Analyst / Broker||Action||Previous target||Current target||Diff|
|2019-4-5||Mizuho||Set Price Target||n/a||$103.00||-|
|2019-2-1||Jefferies Financial Group||Downgrades||n/a||$95.00||-|
Financials and fundamental analysis
Earnings date and Earnings per ShareSince May, when Celgene presented its last earnings report, it remained steady a neutral 0.73%. Unfortunately, reported EPS is not yet available in our database.
|Quarter||Reporting date||Estimated EPS||Actual EPS||Surprise|
Annual financial resultsCompared to 2017, last anual turnover report draw a super good increase of 17.52% to $15,281.00 million USD. However, its earnings margin (compared to sales) raised to 26.48%, that is $4,046.00 million. To have an up to date picture of the financial situation of Celgene, we have calculated the trailing twelve month (TTM) sales and income figures. TTM values are the sum of the last 4 quarters and aproximate to an annual fiscal report ending in 2019-Q1 that can be compared to 2018 fiscal year results. Annual Celgene TTM sales up to March 2019 were $15,768.00 and income was $4,745.00 million dollars. If we compare this TTM figures with the last reported annuality, we can review Celgene business evolution since December 2018: Annual turnover up to March, compared to lastest yearly report, gained a decent 3.19%. In line, profit margin (net income/sales) stepped up at 26.48%.
|2013||$6,480 M||-||$1,450 M22.4%||-|
|2014||$7,670 M||18.37%||$2,000 M26.1%||37.92%|
|2015||$9,256 M||20.67%||$1,602 M17.3%||-19.90%|
|2016||$11,229 M||21.32%||$1,999 M17.8%||24.79%|
|2017||$13,003 M||15.80%||$2,940 M22.6%||47.06%|
|2018||$15,281 M||17.52%||$4,046 M26.5%||37.62%|
|TTM||$15,768 M||3.19%||$4,745 M30.1%||17.28%|
Quarterly financial resultsCelgene reported $4,025.00 million in sales for 2019-Q1, a -0.30% decline compared to previous quarter. Reported quarter income marked $1,545.00 million with a profit margin of 38.39%. Profit margin skyrocketed a 11.81% compared to previous quarter when profit margin was 26.58%. When comparing revenues to same quarter last year, Celgene sales marked an extraordinary increase and boosted a 13.76%.
|2017-Q2||$3,190 M||-||$1,060 M33.2%||-|
|2017-Q3||$3,280 M||2.82%||$988 M30.1%||-6.79%|
|2017-Q4||$3,483 M||6.19%||$-81 M-2.3%||-108.20%|
|2018-Q1||$3,538 M||1.58%||$846 M23.9%||-1,144.44%|
|2018-Q2||$3,814 M||7.80%||$1,045 M27.4%||23.52%|
|2018-Q3||$3,892 M||2.05%||$1,082 M27.8%||3.54%|
|2018-Q4||$4,037 M||3.73%||$1,073 M26.6%||-0.83%|
|2019-Q1||$4,025 M||-0.30%||$1,545 M38.4%||43.99%|
Celgene ownershipWhen you are planning to buy shares of a stock, it's always worth to have a look its ownership structure.
Celgene shares owned by insiders (that is, founders, CEO, CTO, main executives or other management staff) currently counts a 0.22% of all shares.
In case of Celgene stock, 77.62% of its shares are held by institutions (mutual funds, pension funds, big banks and other large financial institutions). Bearish positions for CELG stock account 0.00%, no big difference from last month.
The following table compares ownership indicators for other stocks related to Celgene:
|Market cap||$67.1 B||$25.8 B||$124.1 B||$45.2 B||$943.5 M|
|Total shares||701.0 M||224.3 M||609.9 M||193.9 M||69.5 M|
|Float shares||706.3 M||223.6 M||598.3 M||184.0 M||76.3 M|
|- Institutional holdings (%)||77.6%||96.8%||81.9%||93.4%||93.2%|
|- Insider holdings (%)||0.2%||0.3%||0.2%||0.5%||4.9%|
|Shares in short selling||0.0%||0.0%||0.0%||0.0%||0.0%|
|Thursday, August 22nd, 2019|
|Day range||$95.16 - $95.99|
|Average true range||$1.13|
|50d mov avg||$93.65|
|100d mov avg||$94.25|
|200d mov avg||$87.36|
Celgene performanceStocks performance is always measured in comparision to the market or competitors and related stocks in the same industry. We chose Alexion Pharmaceuticals, Amgen, Biogen, Epizyme, Gilead Sciences, Illumina, , Eli Lilly and and Acceleron Pharma as the bechmarking frame for Celgene stock.
|LLYEli Lilly and||-4.03%||-9.10%||7.68%|
Celgene competitorsWe chose a few stocks to conform a list of Celgene competitors to check if you are interested in investing in CELG:
- Alexion Pharmaceuticals (ALXN)
- Amgen (AMGN)
- Biogen (BIIB)
- Epizyme (EPZM)
- Gilead Sciences (GILD)
- Illumina (ILMN)
- Eli Lilly and (LLY)
- Acceleron Pharma (XLRN)
Latest Celgene stock news
- InvestorPlaceNasdaq Today: Celgene, Ulta, Caesars’ BuyoutJune 24, 2019
- Seeking AlphaBristol-Myers Squibb And Celgene - On The Path To A Valuable CombinationJune 20, 2019
- Seeking AlphaCelgene's Long Journey Through Regulatory Filings For Ozanimod Might Finally Pay OffJune 12, 2019
- InvestorPlace3 Big Stock Charts for Monday: American Airlines Group, Mylan and CelgeneMay 6, 2019
- Seeking AlphaCelgene And Acceleron: BLA Luspatercept Has Strong PotentialApril 11, 2019